Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

John F Seymour, MD, FRACP, Valeria Santini, MD, Pierre Fenaux, MD, Aristoteles A.N. Giagounidis, MD, Guillermo F. Sanz, MD, PhD, Carlo Finelli, MD, Lela M. Lucy, MS, Jay Backstrom, MD, MPH, CL Beach, PharmD

Blood (2010) 116 (21): 1856.

https://doi.org/10.1182/blood.V116.21.1856.1856

Published: 2010

Journal Articles

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Steven D. Gore, MD, Valeria Santini, MD, Pierre Fenaux, MD, PhD, Lewis R. Silverman, MD, Anne Hagemeijer, MD, Barry Skikne, MD, Eva Hellstrom-Lindberg, MD, PhD, John F. Seymour, MBBS, PhD, FRACP, CL Beach, PharmD, Jay Backstrom, MD, MPH, Indrasiri Fernando, PhD

Blood (2009) 114 (22): 1755.

https://doi.org/10.1182/blood.V114.22.1755.1755

Published: 2009

Journal Articles

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 3629.

https://doi.org/10.1182/blood.V112.11.3629.3629

Published: 2008

Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD

Blood (2008) 112 (11): 1653.

https://doi.org/10.1182/blood.V112.11.1653.1653

Published: 2008

Journal Articles

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, Linda Zimmerman, BSN, David McKenzie, MS, C. L. Beach, PharmD, Lewis B. Silverman, MD

Blood (2008) 112 (11): 3636.

https://doi.org/10.1182/blood.V112.11.3636.3636

Published: 2008

Journal Articles

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lewis R. Silverman, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Valeria Santini, MD, Eva Hellström-Lindberg, MD, PhD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 227.

https://doi.org/10.1182/blood.V112.11.227.227

Published: 2008

NARROW

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only